Revenue
2018
2019
2020
2021
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.82B | $2.11B | $2.19B | $2.39B | $2.11B | $2.02B | $2.15B | $2.59B | $2.31B | $3.02B | $3.42B | $6.10B |
| Gross profit | $549.0M | $618.0M | $668.0M | $830.0M | $670.0M | $599.0M | $651.0M | $863.0M | $729.0M | $887.0M | $888.0M | $1.52B |
| Research & development | $54.0M | $55.0M | $51.0M | $55.0M | $50.0M | $56.0M | $58.0M | $73.0M | $73.0M | $87.0M | $99.0M | $114.0M |
| Operating income | −$775.0M | −$26.0M | $172.0M | $333.0M | $192.0M | −$461.0M | $86.0M | $102.0M | $49.0M | −$50.0M | $112.0M | $46.0M |
| EBITDAderived | −$538.0M | $248.0M | $415.0M | $574.0M | $436.0M | −$226.0M | $363.0M | $379.0M | $314.0M | $252.0M | $418.0M | $439.0M |
| Net income | −$845.0M | $169.0M | $178.0M | $927.0M | $220.0M | −$508.0M | $505.0M | $114.0M | $1.0M | −$29.0M | $309.0M | $233.0M |
| Basic EPSper diluted share | -$18.23 | $3.40 | $3.36 | $16.71 | $3.63 | -$8.39 | $8.15 | $1.82 | $0.01 | -$0.47 | $4.54 | $3.04 |
| Diluted EPSper diluted share | -$18.23 | $3.36 | $3.31 | $16.41 | $3.59 | -$8.39 | $8.15 | $1.79 | $0.01 | -$0.47 | $4.54 | $3.00 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 31, 2025Form 4 | NOVO GUILLERMOChair of the Board and CEO | BuyCommon Stock · indirect | 31.3K | $64.24 | $2.01M | 31.3K |
| Jan 31, 2025Form 4 | Assis Alessandra FaccinSVP and GM, Life Sciences | BuyCommon Stock | 3.1K | $64.00 | $201.6K | 3.1K |
| Dec 5, 2024Form 4 · 10b5-1 | BONI ERIC NVP, Finance & Prinpl Acctg Off | SellCommon Stock | 451 | $78.07 | $35.2K | 14.2K |
| Nov 19, 2024Form 4 · 10b5-1 | LAMPKIN ROBIN E.SVP, Gen Counsel and Secrty. | SellCommon Stock | 162 | $75.54 | $12.2K | 3.4K |
| Nov 15, 2024Form 4 · 10b5-1 | LAMPKIN ROBIN E.SVP, Gen Counsel and Secrty. | SellCommon Stock | 868 | $77.90 | $67.6K | 2.9K |